A Phase I/II Open Label Study of the 17α-hydroxylase/ C17,20 lyase inhibitor, Abiraterone acetate, in Patients with Prostate Cancer who have failed hormone therapy

Mise à jour : Il y a 4 ans
Référence : EUCTR2005-001166-13

  • | Pays :
  • -
  • | Organes :
  • -
  • | Spécialités :
  • -

Extrait

To evaluate the safety, tolerability and recommended dose of abiraterone acetate administered orally, by continuous once-daily administration in patients with HRPC. To determine the effect of abiraterone acetate on the pituitary-adrenal-gonad endocrine axis and on adrenal hormones by evaluating serum levels of testosterone and its precursors. To evaluate the efficacy of abiraterone acetate in HRPC at recommended dose.


Critère d'inclusion

  • Hormone refractory prostate cancer

Liens